Recalled Medicines & supplements – Current GIS Alerts 2026
Found 698 recalled products in the Medicines & supplements category. Check batch numbers, shops, and hazard information.
Common hazards in this category
All recalled products
Elenium
The identified non-compliance in the parameter of active substance release affects the product’s quality and may impact its effectiveness and safety of use. The acceptance criterion for the minimum amount of released active substance was not met. Potential effects: possible lack of treatment efficacy and related disease complications.
Elenium
The identified non-compliance in the active substance release rate affects the product’s quality and may impact its efficacy and safety. The acceptance criterion for the minimum amount of released active substance was not met. Potential effects: lack of treatment efficacy, deterioration of health, complications related to insufficient drug action.
Elenium
The identified non‑compliance in the active substance dissolution parameter affects product quality and may impact the effectiveness and safety of its use; a risk to human health cannot be excluded. Potential effects: lack of therapeutic effect, adverse reactions, health risk.
Enema
Cloudiness and opalescence of the solution caused by micro sediment originating from the active substance (trace amounts of titanium compounds in the solution); initially suspected quality defect of the medicinal product. Potential effects: possible irritation of the rectal mucosa or reduced treatment efficacy.
Soliris
Risk of confusion among medical staff due to information on the route and method of administration being given in Slovak and Czech on the vial. Potencjalne skutki: incorrect administration of the drug, treatment complications, risk to patient health.
Soliris
Incorrect vial labeling was found – the phrases “concentrate for solution for infusion”, “for intravenous use”, “dilute before use” were in Slovak and Czech, which may hinder correct administration and a risk to health cannot be excluded. Potential effects: serious administration errors, lack of efficacy or treatment complications.
Bupivacaine and Epinephrine, Bupivacaine-Epinephrine 0,5%,
A change in solution colour from clear to opalescent, brown or yellow was reported. Product with changed colour must not be used and must be discarded; it is a solution for injection. Potential effects: possible toxic action or lack of anaesthetic efficacy, adverse reactions after injection.
Bupivacaine and Epinephrine, Bupivacaine-Epinephrine 0,5%,
The product is a solution for injection; a change in colour from clear to opalescent, brown or yellow may indicate drug degradation; a discoloured product must not be used and must be discarded. Potential effects: lack of efficacy, adverse reactions or complications after administration of a solution of inadequate quality.
DEXAPINI
At the same time, the document stated that “crystallisation of sugar reduces the sugar concentration in the remaining liquid, which may theoretically lead to microbiological contamination.” The GIF indicated a real risk of loss of batch quality, especially after first opening the bottle. Potential effects: possible microbiological contamination of the syrup, risk of infection and lack of safe use.
Veriflo
Negative result of quality tests: non-compliant mean content in the delivered dose between containers for fluticasone propionate and salmeterol and lack of uniformity of the delivered dose; this parameter was deemed critical for the efficacy and safety of product use. Potential effects: impaired disease control, lack of treatment efficacy, or adverse effects related to incorrect dosing.
Liv 52
It was found that the medicinal product documentation was not updated to current European Pharmacopoeia requirements, so the quality of the medicine cannot be properly verified. Potential effects: possible unknown product quality, lack of efficacy or unpredictable adverse reactions.
Liv 52
a medicinal product whose quality cannot be properly verified due to the company’s failure to update the documentation that serves as the reference point for assessing the product’s quality. Potential effects: lack of efficacy, unpredictable adverse reactions.
Pectosol
Leakage from unit packs was found, caused by incompatibility of the bottle with the cap, and an out-of-specification result for the “content in the container” parameter; the impact of this non-compliance on product safety until the end of shelf-life cannot be ruled out. Potential effects: incorrect dosing, reduced efficacy or increased adverse effects.
Pectosol
Leakage from unit packs caused by incompatibility of the bottle with the cap and an out-of-specification result for the “content in the package” parameter were found, which may affect safety of use until the end of shelf life. Potential effects: lack of treatment efficacy, possible irritation or complications if the product becomes contaminated.
Hemkortin-HC
The non-compliance indicated by OMCL may affect the quality of this product and the safety of its use, and therefore a risk to human health from keeping this batch of the medicinal product on the market cannot be excluded. Potential effects: lack of treatment efficacy, possible complications of the underlying disease.
Hemkortin-HC
The non-compliance in the parameter “zinc sulfate monohydrate content” indicated by OMCL may affect product quality and safety of use, and therefore a risk to human health cannot be excluded. Potential effects: lack of treatment efficacy, possible disease complications, skin reactions.
Septogard Plus
Exceeding the upper specification limit for “Related substances. Unspecified Cetylpyridinium impurity” was found, which may affect product quality and safety of use and may pose a risk to human health. Potential effects: impaired drug efficacy, adverse reactions, complications.
Septogard Plus
Exceeding the upper specification limit for the parameter “Related substances. Unspecified Cetylpyridinium impurity”, which may affect product quality and safety of use, therefore a risk to human health cannot be excluded. Potential effects: possible adverse effects and uncertainty regarding the product’s safety and efficacy.
Cefazolin TZF
The presence of brown liquid was found in some vials instead of white or almost white powder, indicating a quality defect of the product and possible impact on the safety of its use. Potential effects: lack of therapeutic efficacy, complications after intravenous or intramuscular administration, and unpredictable adverse reactions.
Cefazolin TZF
The presence of brown liquid was found in some vials instead of white or almost white powder, indicating a serious quality defect that may affect the product’s safety and efficacy. Potential effects: lack of treatment efficacy, infections, severe complications after intravenous administration.
What to do if you bought a recalled product?
If you have purchased any of the products listed above, stop using or consuming them immediately. You can return the product to the store where you bought it for a full refund. Keep the receipt if possible, but most stores will accept returns even without one.